56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)
D-Y. Oh, A.R. He, S. Qin, L-T. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasanvimon, R.E. Zaucha, A. Avallone, J.E. Cundom, N. Rokutanda, M. Watras, G. Cohen, J.W. Valle
Topics & Concepts
MedicineGemcitabineDurvalumabCisplatinBiliary tract cancerInternal medicinePlaceboOncologyGastroenterologyCancerChemotherapyPathologyImmunotherapyNivolumabAlternative medicineCholangiocarcinoma and Gallbladder Cancer StudiesPancreatic and Hepatic Oncology ResearchPeptidase Inhibition and Analysis